dc.contributor.author | Dyer, Ariann | |
dc.contributor.author | De Faria, Alix | |
dc.contributor.author | Julio, Gemma | |
dc.contributor.author | de Toledo, Juan Álvarez | |
dc.contributor.author | Barraquer, Rafael I. | |
dc.contributor.author | Fideliz de la Paz, Maria | |
dc.date.accessioned | 2024-02-05T15:39:57Z | |
dc.date.available | 2024-02-05T15:39:57Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Dyer, Ariann; De Faria, Alix; Julio, Gemma [et al.]. Long-term anatomical and functional survival of Boston Type 1 keratoprosthesis in congenital aniridia. Frontiers in Medicine, 2021, 8, 749063. Disponible en: <https://www.frontiersin.org/articles/10.3389/fmed.2021.749063/full>. Fecha de acceso: 5 feb. 2024. DOI: 10.3389/fmed.2021.749063 | ca |
dc.identifier.issn | 2296-858X | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/4016 | |
dc.description.abstract | Purpose: To analyze the long-term anatomical survival, functional survival, and complications of Boston type 1 keratoprosthesis (KPro) in the eyes with congenital aniridia-associated keratopathy (AAK). Methods: A retrospective review of 12 eyes with congenital aniridia that underwent a Boston type 1 KPro surgery was conducted. A Kaplan–Meier analysis was performed. Anatomical and functional success criteria were KPro retention and a best corrected visual acuity (BCVA) ≤1.3 LogMAR (≥0.05 decimal) at the end of a follow-up period. Postoperative complications were recorded. Results: The mean preoperative BCVA was 2.1 ± 0.9 (range: 3.8–1) LogMAR, and glaucoma was a comorbidity in all the cases. Five years after the surgery, the overall retention rate was 10/12 (83.3%), and 50% had functional success. Only three (25%) of the 12 cases did not achieve a BCVA ≤1.3 LogMAR. The cumulative probability of anatomical success was 92, 79, and 79% after 1, 5, and 10 years, respectively. The cumulative probability of functional success was 57 and 46% after 1 and 5 years, respectively. The mean anatomical and functional survival time was 10 ± 1.3 (95% IC = 7.5–12.3 years) and 3.8 ± 0.9 years (95% IC = 1.8–5.8 years), respectively. The most common postoperative complication was retroprosthetic membrane (RPM) formation in 8/16 cases (66%). The mean number of complications per case was 2.4 ± 1.8 (0–6). Conclusions: The Boston type 1 KPro is a viable option for patients with AAK with good anatomical and functional long-term results. Glaucoma is an important preoperative condition that affects functional results. Retroprosthetic membrane formation seems to have a higher incidence in this condition. | ca |
dc.format.extent | 6 | ca |
dc.language.iso | eng | ca |
dc.publisher | Frontiers Media | ca |
dc.relation.ispartof | Frontiers in Medicine | ca |
dc.relation.ispartofseries | 8 | |
dc.rights | © 2021 Dyer, De Faria, Julio, Álvarez de Toledo, Barraquer and de la Paz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | ca |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.subject.other | Anirídia | ca |
dc.subject.other | Queratopròtesi de Boston tipus 1 | ca |
dc.subject.other | Extrusió | ca |
dc.subject.other | Membrana retroprotèsica | ca |
dc.subject.other | Anirídia associada | ca |
dc.subject.other | Queratopatia | ca |
dc.subject.other | Aniridia | ca |
dc.subject.other | Queratoprótesis Boston tipo 1 | ca |
dc.subject.other | Extrusión | ca |
dc.subject.other | Membrana retroprotésica | ca |
dc.subject.other | Aniridia asociada queratopatía | ca |
dc.title | Long-term anatomical and functional survival of Boston type 1 keratoprosthesis in congenital aniridia | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.identifier.doi | https://dx.doi.org/10.3389/fmed.2021.749063 | ca |